ImmunoPrecise Awarded First Commercial Humanized Antibody Project

- September 18th, 2017

ImmunoPrecise announced it was awarded the first commercial humanizing antibody project from an undisclosed biotech company.

ImmunoPrecise Antibodies (TSXV:IPA; OTCPINK:IPATF) announced it was awarded the first commercial humanizing antibody project from an undisclosed biotech company.
As quoted in the press release:

This project builds on the Company’s recent R&D projects with two established biotech companies (see press release dated April 11, 2017) which produced successful results developing human monoclonal antibodies (see press release dated August 29, 2017) using its unique and proprietary methodologies, including its RapidPrime™ immunization protocol. ImmunoPrecise’s proprietary RapidPrime™ method identifies positive monoclonal antibodies in as little as 32 days.
“With this significant humanizing project award, we are expanding into one of the higher margin business segments we have been targeting and executing on one of our key strategic growth areas,” said Tom D’Orazio, CEO of ImmunoPrecise.

Click here to read the full press release.

Get the latest Biotech Investing stock information

Get the latest information about companies associated with Biotech Investing Delivered directly to your inbox.

Biotech Investing

Select All
Select None

By selecting company or companies above, you are giving consent to receive email from those companies. And remember you can unsubscribe at any time

Leave a Reply

Your email address will not be published. Required fields are marked *